SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

Pictured: Man carrying a box of his office items after being laid off
Drug Development
Aeglea Cuts Majority of Staff Following Mixed Trial Results
Following mixed Phase I/II data for its homocystinuria hopeful pegtarviliase, Aeglea lays off all but 10 employees and launches a sweeping strategic review.
April 12, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Facade of Moderna's building in Massachusetts
Drug Development
Moderna’s Flu Shot Falls Short of Early Success Threshold
An interim analysis of the Phase III P302 study showed Moderna’s investigational flu shot, mRNA-1010, fell short of the statistical threshold for early success.
April 12, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Elizabeth Holmes/Courtesy Yichuan Cao/Nu
Policy
Holmes to Remain in Prison While Appeal Plays Out
A California judge denied Elizabeth Holmes’ motion for release pending appeal, ruling that the former Theranos CEO must serve her prison sentence while she appeals her guilty verdict.
April 12, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Doctor holding model of kidney/Shidlovsk
Drug Development
HI-Bio Advances Rare Kidney Disease Therapy to Late-Stage Studies
Data from two mid-stage studies show HI-Bio’s investigational therapy felzartamab lowers pathogenic antibody titers in patients with primary membranous nephropathy (PMN).
April 11, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Gavel/Courtesy of Getty Images
FDA
Appellate Court Partially Blocks Texas Abortion Pill Ruling
In an open letter published Monday, more than 480 biopharma industry leaders expressed their support for the FDA after a Texas federal judge ruled to hold the approval of the abortion pill mifepristone.
April 11, 2023
 · 
3 min read
 · 
Tristan Manalac
John Tlumacki/The Boston Globe via Getty Images
Business
In Another Round of Cuts, Biogen Lays Off Unspecified Number of Employees
The Boston Business Journal reported the layoffs would affect the multiple sclerosis team, but Biogen declined to confirm the details.
April 10, 2023
 · 
2 min read
 · 
Tristan Manalac
AbbVie_© AbbVie Inc. All rights reserved.
Drug Development
AbbVie, J&J Pull Two Accelerated Approvals for Imbruvica
AbbVie and Johnson & Johnson will withdraw the accelerated approvals for Imbruvica in mantle cell lymphoma and marginal zone lymphoma, the companies announced Thursday.
April 10, 2023
 · 
2 min read
 · 
Tristan Manalac
Sarah Silbiger/Getty Images
FDA
FDA Action Alert: Alvotech, Otsuka and More
The FDA is set to decide on a Humira biosimilar and hold an Adcomm meeting for an Alzheimer’s agitation treatment. Also on its calendar for April are decision dates for two vaccine hopefuls.
April 7, 2023
 · 
4 min read
 · 
Tristan Manalac
Kirkland, Quebec, Canada - September 3, 2021: Merck Canada head office in Kirkland, Quebec, Canada. Merck is an American multinational pharmaceutical company.
Drug Development
Merck/Eisai Drops Melanoma Program for Keytruda-Lenvima Combo After Phase III Fail
Results from two late-stage trials showed the Merck-Eisai combo treatment failed to boost survival in two difficult-to-treat advanced cancers.
April 7, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy of JHVEPhoto/Getty Images
Drug Development
Pfizer Publishes Phase III RSV Data Ahead of May Decision
Phase III data for Pfizer’s respiratory syncytial virus vaccine candidate showed high levels of protection for older adults and infants.
April 6, 2023
 · 
2 min read
 · 
Tristan Manalac
Courtesy Bodo Marks/Picture Alliance via Getty Ima
Drug Development
AstraZeneca’s Imfinzi/Lynparza Combo Boosts Survival in Ovarian Cancer
AstraZeneca’s Imfinzi and Lynparza met primary endpoint markers in the Phase III DUO-O trial in advanced high-grade epithelial ovarian cancer, according to data released Wednesday.
April 5, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: Medical professional giving COVID Test/C
Drug Development
FDA Grants EUA to InflaRx’s Anti-Inflammatory COVID-19 Treatment
The FDA has granted emergency use authorization to InflaRx’s vilobelimab, now to be marketed as Gohibic, for hospitalized adult patients with COVID-19, the German biotech announced Tuesday.
April 5, 2023
 · 
2 min read
 · 
Tristan Manalac
Pictured: A corporate building overlooking a freew
Business
Cure Ventures Launches with $350M to De-Risk Innovation
With an inaugural $350 million fund, Cure Ventures launched Tuesday to support early-stage companies with cutting-edge curative technologies and help them de-risk their science
April 4, 2023
 · 
2 min read
 · 
Tristan Manalac
Physician holds up hand in a stop sign signal_Shut
Drug Development
Gossamer Cuts Lymphoma Drug After Two Fatalities
Gossamer Bio announced Monday that it is discontinuing the development of its lymphoma candidate, GB5121, following two patient deaths in the Phase Ib/II STAR-CNS study.
April 4, 2023
 · 
2 min read
 · 
Tristan Manalac
Drug Development
FDA Approves Keytruda/Padcev Combo in Advanced Urothelial Cancer
The FDA has approved the combination regimen of Merck’s Keytruda and Seagen and Astellas’ Padcev for the first-line treatment of locally advanced or metastatic urothelial carcinoma.
April 4, 2023
 · 
2 min read
 · 
Tristan Manalac
Load More